Caris Life Sciences, Inc.

Name: Caris Life Sciences, Inc. standardized financial statements, quarterly
Creator: Listed

CAINasdaqCIK 2019410HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$263.7m, Q2 FY2026

Operating income$26.9m, Q2 FY2026

Net income−$637.0k, Q2 FY2026

Caris Life Sciences, Inc., income statement, quarterly
Line item	Unit	period not labelled2024-06-30	period not labelled2024-09-30	period not labelled2024-12-31	period not labelled2025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	100	102	130	121	181	217	293	216	264
Research and development	$m	24.8	27.6	27.1	23.1	25.0	21.6	31.8	31.3	32.4
Operating income	$m	(67.0)	(60.8)	(37.0)	(58.0)	(18.0)	32.6	88.4	5.3	26.9
Interest expense	$m	13.7	13.8	13.3	12.8	19.2	13.5	11.4	12.8	9.2
Income tax	$m	0.0	0.0	0.0	0.0	0.0	0.0	0.0	(0.1)	0.0
Net income	$m	(66.2)	(67.7)	(36.9)	(103)	(71.8)	24.3	82.0	(0.5)	(0.6)
Diluted EPS	$ per share	(2.54)	(2.59)	not reported	(3.57)	(7.97)	0.08	not reported	0.00	0.00
Basic EPS	$ per share	(2.54)	(2.59)	not reported	(3.57)	(7.97)	0.09	not reported	0.00	0.00

Balance sheet

Cash and equivalents$819.9m, Q1 FY2026

Long-term debt$393.0m, Q2 FY2026

Shareholders' equity$591.7m, Q2 FY2026

Caris Life Sciences, Inc., balance sheet, quarterly
Line item	Unit	period not labelled2022-12-31	period not labelled2023-12-31	period not labelled2024-03-31	period not labelled2024-06-30	period not labelled2024-09-30	period not labelled2024-12-31	period not labelled2025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	not reported	not reported	not reported	not reported	not reported	64.0	31.2	719	753	796	820	not reported
Current assets	$m	not reported	not reported	not reported	not reported	not reported	216	not reported	833	854	998	1,014	1,058
Total assets	$m	not reported	not reported	not reported	not reported	not reported	344	not reported	955	985	1,126	1,162	1,230
Current liabilities	$m	not reported	not reported	not reported	not reported	not reported	165	not reported	90.2	86.0	127	144	191
Total liabilities	$m	not reported	not reported	not reported	not reported	not reported	621	not reported	502	506	548	569	638
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	319	not reported	374	376	379	381	393
Current portion of debt	$m	not reported	not reported	not reported	not reported	not reported	60.1	not reported	0.1	0.2	0.2	0.2	0.2
Shareholders' equity	$m	(1,702)	(2,145)	(2,275)	(2,360)	(2,442)	(2,499)	(2,600)	453	478	577	593	592

Cash flow

Operating cash flow$28.5m, Q2 FY2026

Capital expenditure$22.1m, Q2 FY2026

Share repurchases$21.4m, Q2 FY2026

Caris Life Sciences, Inc., cash flow, quarterly
Line item	Unit	period not labelled2024-09-30	period not labelled2024-12-31	period not labelled2025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(69.4)	(38.9)	(31.3)	7.3	62.4	44.8	32.9	28.5
Capital expenditure	$m	1.8	2.3	2.7	1.4	7.1	5.1	10.3	22.1
Share repurchases	$m	0.0	0.0	0.0	0.0	0.0	0.1	0.0	21.4

Diluted shares (weighted)282.89m, Q2 FY2026

Caris Life Sciences, Inc., shares, quarterly
Line item	Unit	period not labelled2024-06-30	period not labelled2024-09-30	period not labelled2025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	35.4	35.6	35.6	64.9	297	283	283

Shares outstanding: 282.60m at Aug 3, 2026, from the cover of the 10-Q filed Aug 5, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. Listed shows no prices and gives no investment advice.